文献速递肾癌与肾肿瘤

基因组与表观基因组特征可区分侵袭性嫌色细胞肾细胞癌与惰性肾嗜酸细胞肿瘤

Genomic and Epigenomic Signatures Can Distinguish Aggressive Chromophobe Renal Cell Carcinoma from Indolent Renal Oncocytic Tumors in Clinical-grade Samples.
PubMed 文献 · Eur Urol Oncol · 2025-11-04

本研究对68例肾切除样本进行靶向外显子测序、基因表达谱和全基因组甲基化测序,并分析TCGA中66例嫌色细胞肾细胞癌(ChRCC)数据,旨在区分惰性肾嗜酸细胞肿瘤与侵袭性ChRCC。研究发现7-11基因表达特征和8-CpG甲基化特征可有效区分侵袭性ChRCC,TP53和PTEN突变显著增加侵袭性概率。

要点

  • 7-11基因表达特征区分侵袭性ChRCC的交叉验证AUC为0.77-0.85,外部验证AUC为0.88。
  • 8-CpG甲基化特征区分侵袭性ChRCC的交叉验证AUC为0.86,外部验证AUC为0.91。
  • TP53和PTEN突变大幅增加侵袭性ChRCC的概率。

核心结论

  • 常规FFPE肿瘤组织的基因组和表观基因组特征有助于区分侵袭性ChRCC与惰性肾嗜酸细胞肿瘤(包括惰性ChRCC)。

研究设计与样本

  • 对68例肾切除样本(44例惰性肾嗜酸细胞肿瘤,24例侵袭性ChRCC)进行靶向外显子测序、基因表达谱和全基因组甲基化测序,并分析TCGA中66例ChRCC数据。

主要发现

  • 7-11基因表达特征区分侵袭性ChRCC与惰性ChRCC及其他惰性肾嗜酸细胞肿瘤,十折交叉验证AUC=0.77-0.85,外部验证AUC=0.88。
  • 8-CpG甲基化特征区分侵袭性ChRCC,十折交叉验证AUC=0.86,外部验证AUC=0.91。
  • TP53和PTEN突变显著增加侵袭性ChRCC的概率。

关键数值与推荐

  • 7-11基因表达特征:十折交叉验证AUC=0.77-0.85,外部验证AUC=0.88。
  • 8-CpG甲基化特征:十折交叉验证AUC=0.86,外部验证AUC=0.91。
  • TP53和PTEN突变与侵袭性ChRCC概率增加相关。

临床怎么用

  • 对常规FFPE样本进行基因组和表观基因组特征检测,可辅助区分侵袭性ChRCC与惰性肾嗜酸细胞肿瘤,为患者管理、安抚和随访提供依据。

局限性

  • 样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Only a minority of renal oncocytic tumors are aggressive. These tumors' behavior is difficult to predict by histopathological evaluation; consequently, many patients experience anxiety upon diagnosis and may undergo unnecessary treatment. Our aim was to derive genomic and epigenomic signatures to distinguish clinically indolent renal oncocytic tumors from aggressive chromophobe renal cell carcinoma (ChRCC). METHODS: We performed molecular profiling of nephrectomies from 68 patients: 44 with indolent renal oncocytic tumors (19 renal oncocytoma, two oncocytic renal neoplasm of low malignant potential, and 23 indolent ChRCC) and 24 with aggressive ChRCC. We performed targeted exome sequencing, gene expression profiling, and whole-genome methylation sequencing of formalin-fixed, paraffin-embedded (FFPE) samples. We also analyzed The Cancer Genome Atlas Kidney Chromophobe data from 66 ChRCC patients in silico. Genomic and epigenomic signatures linked to aggressive ChRCC-obtained from sampling morphologically nonsarcomatoid foci-from both cohorts were derived using the least absolute shrinkage and selection operator method. KEY FINDINGS AND LIMITATIONS: Aggressive ChRCC was distinguished from indolent ChRCC and other indolent renal oncocytic tumors using a focused seven- to 11-gene expression signature (ten-fold cross-validation [CV] area under the curve [AUC] = 0.77-0.85) with an external validation AUC of 0.88, and an eight-CpG methylation signature (ten-fold CV AUC = 0.86) with an external validation AUC of 0.91. TP53 and PTEN mutations substantially increased the probability of aggressive ChRCC. Limitations include the small sample size. CONCLUSIONS AND CLINICAL IMPLICATIONS: Focused genomic and epigenomic signatures from routinely processed FFPE tumor tissues can help distinguish aggressive ChRCC from indolent renal oncocytic tumors, including indolent ChRCC. This forms the basis for replication studies to inform appropriate patient management, provide reassurance, and guide follow-up.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Ruiz-Cordero R, Wang Q, Kumar G, et al. Genomic and Epigenomic Signatures Can Distinguish Aggressive Chromophobe Renal Cell Carcinoma from Indolent Renal Oncocytic Tumors in Clinical-grade Samples. Eur Urol Oncol. 2025. PMID: 41193273. doi:10.1016/j.euo.2025.09.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。